Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis

Tatiana Barichello1,3,4*, João Carlos Nepomuceno Gonçalves1,3,4, Jaqueline S Generoso1,3,4, Grazielle L Milioli1,3,4, Cintia Silvestre1,3,4, Caroline S Costa1,3,4, Jaqueline da Rosa Coelho1,3,4, Clarissa M Comim2,3,4 and João Quevedo2,3,4

Abstract

Background: Streptococcus pneumoniae is associated with neurologic sequels, such as, seizures, sensory-motor deficits, hearing loss, learning and memory impairment, which can occur in approximately 30 to 52% of surviving patients. Neuronal damage can be caused by intense inflammatory reaction and direct effects of the bacteria virulence factors. The aim of the present study was to evaluate the effects of the nonbacteriolytic antibiotic daptomycin versus ceftriaxone on behavioral parameters in adult Wistar rats submitted to pneumococcal meningitis.

Results: Ten days after induction we verified that the meningitis group with daptomycin treatment showed retention of aversive memory; it presented memory of the object recognition at short term and long term. In continuous multiple-trials step-down inhibitory avoidance task the meningitis group with ceftriaxone treatment required approximately two times more stimulus to reach the acquisition criterion when compared with meningitis group with daptomycin treatment. However, in the habituation memory test there were no differences in the number of crossings and rearings in training and task sessions demonstrating habituation impairment to the environment task in both meningitis groups.

Conclusions: The evidence of the present study shows the potential alternative of the treatment with daptomycin in preventing learning and memory impairments caused by pneumococcal meningitis. Further investigations are necessary to provide support for evaluation of daptomycin as an alternative treatment of bacterial meningitis.

Keywords: Streptococcus pneumoniae, Meningitis, Behavior, Memory, Daptomycin

Background

Pneumococcal meningitis is a life-threatening disease associated with high mortality and morbidity rates. Streptococcus pneumoniae meningitis mortality ranges from 16 to 37% and it is associated with neurologic sequels, such as, seizures, sensory-motor deficits, hearing loss, learning and memory impairment, which can occur in approximately 30 to 52% of surviving patients [1-5]. This microorganism can multiply within the cerebrospinal fluid (CSF) and it leads to the release of bacterial components, which stimulates the production of cytokines and other pro-inflammatory molecules in response to bacterial stimuli [6]. As consequence, polymorphonuclear are attracted, activated and released in large amounts of superoxide anion and nitric oxide, leading to oxidative stress. This cascade leads to mitochondrial damage and blood–brain barrier breakdown. Both damages contribute to cell injury during pneumococcal meningitis. The immune response in cerebrospinal fluid has shown to play a key role in this pathophysiology, principally to the development of the brain damage [7]. Neuronal damage can be caused by
intense inflammatory reaction and by direct effects of the bacteria virulence factors [8]. The hippocampus is surrounded by interstitial fluid which is contiguous with the CSF, allowing bacterial toxins and pro-inflammatory mediators to propagate into the parenchyma [9].

A nonbacteriolytic antibiotic but with high bactericidal properties would minimize the cognitive damage. Since, during the treatment with bacteriolytic antibiotics it could contribute to increase the inflammation in the subarachnoid space also through the release of bacterial components [10]. Daptomycin is an antibacterial agent active against Gram-positive bacteria [11]. The bactericidal activity occurs by irreversible binding within the bacterial cell membrane in a calcium-dependent process. This leads to depolarization of the cell membrane and inhibition of the RNA, DNA and protein synthesis, which results in rapid bacterial cell death without triggering immediate cell lysis [12]. Thus, in experimental pneumococcal meningitis it has been demonstrated that daptomycin produces an enhanced bactericidal activity [13]; it attenuates the CSF inflammation [14] and also prevented cortical brain injury when compared to ceftriaxone treatment [15].

In this context, the aim of the present study was to evaluate the effects of the nonbacteriolytic antibiotic daptomycin versus ceftriaxone on behavioral parameters in adult Wistar rats submitted to pneumococcal meningitis.

Methods

Infecting organism

*S. pneumoniae* (serotype 3) was cultured overnight in 10 ml of Todd Hewitt broth, diluted in fresh medium and grown to logarithmic phase. This culture was centrifuged for 10 min at (5,000×g) and resuspended in sterile saline to the concentration of 5×10^9 cfu/ml. The size of the inoculum was confirmed by quantitative cultures [16,17].

Animal model of meningitis

Adult male Wistar rats (250–350 g body weight), from our breeding colony were used for the experiments. All procedures were approved by the Animal Care and Experimentation Committee of UNESC, Brazil, and followed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications No. 80–23) revised in 1996. All surgical procedures and bacterial inoculations were performed under anesthesia, consisting of an intraperitoneal administration of ketamine (6.6 mg/kg), xylazine (0.3 mg/kg), and acepromazine (0.16 mg/kg) [18]. Rats underwent a cisterna magna tap with a 23-gauge needle. The animals received either 10 μl of sterile saline as a placebo or an equivalent volume of *S. pneumoniae* suspension. At the time of inoculation, animals received fluid replacement and were subsequently returned to their cages [19,20].

Eighteen hours later, the meningitis was documented by a quantitative culture of 5 μl of CSF obtained by puncture of the cisterna magna [16]. The animals were randomly in three different groups sham (control group), meningitis with daptomycin treatment and meningitis with ceftriaxone treatment. The daptomycin (Cubicin®; 50 mg/kg body weight) and ceftriaxone (100 mg/kg body weight) were administered subcutaneously (s.c.) during 7 days.

After 10 days, the animals were free from infection. We performed blood cultures that were all negative in this period. Thus, the animals were separately undergone to four behavioral tasks: a) open field; b) object recognition; c) step-down inhibitory avoidance task (single-training) and d) continuous multiple-trials step-down inhibitory avoidance task.

Behavioral tasks

The animals underwent separately to four behavioral tasks: habituation to an open field, step-down inhibitory avoidance task, continuous multiple-trials step-down inhibitory avoidance task and object recognition. All behavioral procedures were conducted between 13:00 and 16:00 p.m. in a sound-isolated room, and each animal performed only one behavior test. All behavioral tests were recorded by the same person who was blind to the animal group.

Open field test

The behavior was assessed in the open field apparatus in order to evaluate both locomotor and exploratory activities. The apparatus is a 40 cm × 60 cm open field surrounded by 50 cm high walls made of brown plywood with a frontal glass wall. The floor of the open field is divided into 9 rectangles by black lines. The animals were gently placed on the left rear quadrant and then left alone to explore the arena for 5 min (training session). Immediately after this procedure, the animals were taken back to their home cage and 24 h later they were submitted again to a similar open-field session (test session). Every cross of the black lines and rearing performed in both sessions were counted for 5 min. The decrease in the number of crossings and rearings between the two sessions was taken as a measure of the retention of habituation memory [21].

Object recognition

This task evaluates the non-aversive and non-spatial memory. The apparatus and procedures for the object recognition task have been described elsewhere [22]. Briefly, the task took place in a 40 × 50 cm open field surrounded by 50 cm high walls made of plywood with a frontal glass wall. The floor of the open field was divided into 12 equal rectangles by black lines. All animals were submitted to a habituation session where they were
allowed to freely explore the open field for 5 min. No objects were placed in the box during the habituation trial. The total number of crossings of the black lines and rearings performed in this session were evaluated as locomotor and exploratory activity, respectively. The training was conducted by placing individual rats for 5 min in the field, in which two identical objects (objects A1 and A2, both being cubes) were positioned in two adjacent corners, 10 cm from the walls. In a short-term recognition memory test given 1.5 h after training, the rats explored the open field for 5 min in the presence of one familiar (A) and one novel (B, a pyramid with a square-shaped base) object. All objects had similar textures (smooth), colors (blue), and sizes (weight 150–200 g), but distinctive shapes. A recognition index calculated for each animal is reported as the ratio TB/(TA + TB) (TA = time spent exploring the familiar object A; TB = time spent exploring the novel object B). In a long-term recognition memory test given 24 h after training, the same rats were allowed to explore the field for 5 min in the presence of the familiar object A and a novel object C (a sphere with a square shaped base). Recognition memory was evaluated using the same method of the short-term memory test. Exploration was defined as sniffing (exploring the object 3–5 cm away from it) or touching the object with the nose and/or forepaws.

Step-down inhibitory avoidance task
This task evaluates aversive memory. The apparatus and procedures have been described in previous reports [23,24]. Briefly, the training apparatus was a 50 × 25 × 25 cm acrylic box (Albarsch, Porto Alegre, Brazil) which the floor was consisted of parallel caliber stainless steel bars (1 mm diameter) spaced 1 cm apart from each other. A 7 cm-wide, 2.5 cm-high platform was placed on the floor of the box against the left wall. In the training trial, animals were placed on the platform and their latency to step down on the grid with all four paws was measured with an automatic device. Immediately after stepping down on the grid, the animals received a 0.4 mA, 2.0 s foot shock and returned to their home cage. A retention test trial was performed 24 h after training (long-term memory). The retention test trial was procedurally identical to the training, except that no foot shock was presented. The retention test step-down latency (maximum, 180 s) was used as a measure of inhibitory avoidance retention. Reactivity to the foot shock was evaluated in the same apparatus used for inhibitory avoidance, except that the platform was removed. Each animal was placed on the grid and allowed 1 min for habituation period prior to the start of a series of shocks (0.5 s) delivered at 10 s intervals. The shock intensities ranged from 0.1 to 0.5 mA in 0.1 mA increments. The adjustments in the shock intensity were made in accordance to each animal’s response. The intensity was raised by 1 unit when no response occurred and lowered by 1 unit when a response was made. A “flinch” response was defined as the withdrawal of one paw from the grid floor, and a “jump” response was defined as rapid withdrawal of three or four paws. Two measurements of the “flinch” threshold were made and then two measurements of the “jump” threshold were made. For each animal the mean of the two scores for the flinch and the jump thresholds were calculated [25,26].

Continuous multiple-trials step-down inhibitory avoidance task
This task evaluates aversive memory in the test section and learning when analyzing the number of training trials required for the acquisition criterion (see below). It was performed in the same step-down inhibitory avoidance apparatus; however, in the training session, the animals were placed on the platform and immediately after stepping down on the grid, received a 0.3 mA, 2.0 s foot shock. This procedure continued until the rat remained on the platform for 50 s. The animal was then returned to the home cage. The number of training trials required to reach the acquisition criterion of 50 s on the platform was recorded. The retention test was performed 24 h later (long-term memory) [27].

Statistics
Data from the habituation to an open field task is reported as mean ± SEM, and it was analyzed by the paired Student’s t test and ANOVA post-hoc Tukey. Data from the object recognition task and inhibitory avoidance task are reported as median and interquartile ranges, and comparisons among groups were performed using Mann–Whitney U tests. The within-individual groups were analyzed by Wilcoxon’s tests. Data from continuous multiple-trials step-down inhibitory avoidance task the trials were reported as mean ± SD, and were analyzed by the ANOVA post-hoc Tukey. Data from the latency time was reported as median and interquartile ranges, and comparisons among groups were performed using Mann–Whitney U tests. In all comparisons, p<0.05 indicated statistical significance.

Results
In the open-field task, Figure 1, there were no differences in the number of crossings and rearings among groups in the habituation to the open-field training session (p>0.05) demonstrating no difference in motor and exploratory activity among groups. In the sham group, there was statistical difference between training and test session (crossing t = 9.161, df = 9, p = 0.0001; rearings t = 10.672, df = 9, p = 0.0001) demonstrating habituation memory.
In the meningitis/ceftriaxone group (crossing \( t = 1.929, df = 9, p = 0.086 \); rearings \( t = 0.949, df = 9, p = 0.369 \)) and the meningitis/daptomycin group (crossing \( t = 2.195, df = 9, p = 0.056 \); rearings \( t = 0.884 df = 9, p = 0.400 \)) there were no differences between training session and test session suggesting memory impairment in both groups.

The object recognition task in Figure 2, the animals of meningitis/ceftriaxone group presented impairment of novel object recognition memory, i.e., they did not spend a significantly greater time exploring the novel object, presenting memory impairment during short term (Z = −0.866, \( p = 0.386 \)) and long term memory (Z = −0.051, \( p = 0.959 \)). However, the animals of meningitis/daptomycin group did not present memory impairments during short term (Z = −2.499, \( p = 0.012 \)) and long term (Z = −2.395, \( p = 0.017 \)) retention test sessions in comparison to the training trial.

Figure 3, the step-down latency. In the training session there was not significant difference in the latency time among the groups (\( p>0.05 \)). In the meningitis/ceftriaxone group there wasn’t difference in the latency time between training and test (Z=−1.703; \( p=0.089 \)) presenting memory impairment. In the meningitis/daptomycin group there was difference between training and test session (Z=−2.810; \( p=0.005 \)) demonstrating aversive memory in this group.

Figure 4, continuous multiple trials step-down inhibitory avoidance. We demonstrated a significant increase
in the number of training trials \( (t = 3.536, df = 18.541, p = 0.002) \) required to reach the acquisition criterion (50 s on the platform) in the meningitis/ceftriaxone group when compared to the sham group, Figure 4A. The results of this task suggest that the meningitis/ceftriaxone group required approximately two times more stimulus to reach the acquisition criterion when compared with the sham group and with meningitis/daptomycin group. Meningitis/ceftriaxone group had learning and impairment memory. In the retention test, there was no difference among groups for all the times tested, Figure 4B.

![Figure 3 Latency to step-down in the inhibitory avoidance task 10 days after induction of meningitis by S. pneumoniae. Data are reported as median and interquartile ranges, and comparisons among groups were performed using Mann–Whitney U tests, n=10 per group. The within-individual groups were analyzed by Wilcoxon’s tests. *p<0.05 vs. training.](image_url)

![Figure 4 Continuous multiple trials step-down inhibitory avoidance task 10 days after induction of meningitis by S. pneumoniae. Data from the trials is reported as mean ± SD, and were analyzed by the ANOVA post-hoc Tukey, n=10 per group, Figure 4 A. *p<0.05 vs. Sham. Data from the latency time is reported as median and interquartile ranges, and comparisons among groups were performed by Wilcoxon’s tests, Figure 4 B. *p<0.05 vs. Sham.](image_url)
Discussion

In spite of significant advances in pneumococcal meningitis treatment, it remains one of the most important worldwide infectious diseases and it is still correlated with elevated mortality and morbidity. Moreover, a large number of survivors present permanent neurological sequelae [5,6].

The present study suggests a beneficial effect of therapy with daptomycin on memory and learning impairments in an animal model of pneumococcal meningitis. In the habituation memory test there was no difference between treatments with daptomycin and ceftriaxone, both groups demonstrated impairments in this memory. However, the meningitis group with daptomycin treatment showed retention of aversive memory and the animals also presented memory of the object recognition at short term and long term. In continuous multiple-trials step-down inhibitory avoidance task, the meningitis group with ceftriaxone treatment required approximately two times more stimulus to reach the acquisition criterion when compared with meningitis group with daptomycin treatment.

Several studies with daptomycin treatment on experimental pneumococcal meningitis with favorable results have been reported. Daptomycin cleared the bacteria more efficiently from the CSF than ceftriaxone; decreased the inflammatory host response, as assessed by the matrix metalloproteinase-9, IL-1β, IL-10, IL-18, monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 alpha (MIP-1alpha) in CSF and prevented the development of cortical injury [16,28]. During bacterial multiplication into the CSF, it released products that are highly immunogenic and can lead to an increased immune response of the host [10,16]. Whereas, in experimental pneumococcal meningitis model the animals presented, in the first twenty four hours, elevated levels of TNF-α and CINC-1 in the hippocampus and TNF-α, IL-1β, IL-6 and CINC-1 in frontal cortex [29]. Furthermore, the host inflammatory response can be exacerbated by the effects of bacterioclytic antibiotics [30]. The release of teichoic acids (TAs) and lipoteichoic acids (LTAs) from S. pneumoniae showed intense during exposure to ceftriaxone and meropenen [31]. Daptomycin is an antibacterial agent and nonbacteriolytic active against the main Gram-positive pathogens [11,32], including penicillin and cephalosporin resistant pneumococci [33]. Daptomycin was highly efficacious against penicillin-resistant and quinolone-resistant pneumococci [34], in addition, ceftriaxona with adjunctive daptomycin treatment attenuates brain damage and hearing loss more efficiently than rifampin in infant rats induced by pneumococcal meningitis [35]. When the microorganism is killed without lyses, it provides the advantage of reducing the release of bacterial molecules, such as, TAs, LTAs, peptidoglycan and bacterial DNA [36]. These effects could be an explanation for the observation that daptomycin prevented the development of cortical brain injury in experimental pneumococcal meningitis [16] and prevented memory impairment in our study. Previous studies demonstrated that 10 days after pneumococcal meningitis induction animals treated with ceftriaxone presented memory and learning deficits, anxiety-like and depressive-like behavior [37].

Conclusions

The evidence of the present study suggests the potential alternative of the treatment with daptomycin in preventing learning and memory impairments caused by pneumococcal meningitis. Further investigations are necessary to provide support for evaluation of daptomycin as an alternative treatment for bacterial meningitis.

Abbreviations

CFu: colony-forming units; CINC-1: cytokine-induced neutrophil chemoattractant-1; CSF: cerebral spinal fluid; IL-1β: interleukin-1 beta; IL-6: interleukin-6; LTAs: lipoteichoic acids; S. pneumoniae: Streptococcus pneumoniae; TAs: teichoic acids; TNF-α: tumor necrosis factor-α.

Competing interest

The authors have no conflict of interest.

Authors’ contributions

TB conceived of the study, and participated in its design and coordination. JCG, JSG and GM have made substantial contributions to conception and design. CSC and JCR carried out the meningitis induction and acquisitions of data. CMC performed of the statistical analysis. JQ had given final approval of the version to be published. All authors read and approved the final manuscript.

Acknowledgements

This research was supported by grants from CNPq, FAPESC, UNESC, NENASC project (PROEX program CNPq/FAPESC, INCT-TM, Research Support Center on Applied Neuroscience (NAPNA-USP, 2011.1.9333.1.3) and L’Oreal-UNESCO Brazil Fellowship for Women in Science 2011.

Author details

1Laboratório de Microbiologia Experimental, Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88880-000, Criciúma, SC, Brazil. 2Laboratório de Neurociências, Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88880-000, Criciúma, SC, Brazil. 3Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-000, Criciúma, SC, Brazil. 4Núcleo de Excelência em Neurociências Aplicadas de Santa Catarina (NENASC), Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-000, Criciúma, SC, Brazil.

Received: 9 November 2012 Accepted: 12 March 2013
Published: 2 April 2013

References

1. Kastenbauer S, Pfister HW: Pneumococcal meningitis in adults: spectrum of complications and prognostic factors in a series of 87 cases. Brain: a journal of neurology 2003, 126(Pt 5):1015–1025.
2. Van de Beek D, de Gans J: Meningitis-associated hearing loss: protection by adjunctive antioxidant therapy. Annals of neurology 2004, 55(4):597–598. author reply 598.

3. Grimwood K, Anderson P, Anderson V, Tan L, Nolan T: Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Archives of disease in childhood 2000, 83(2):111–116.

4. Hoogman M, van de Beek D, Weissfeld M, de Gans J, Schirmb B: Cognitive outcome in adults after bacterial meningitis. Journal of neurology, neurosurgery, and psychiatry 2007, 78(10):1092–1096.

5. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D: Pathogenesis and pathophysiology of pneumococcal meningitis. Clinical microbiology reviews 2011, 24(3):557–591.

6. Sellner J, Tauber MG, Leib SL: Pathogenesis and pathophysiology of bacterial CNS infections. Handb Clin Neural 2010, 96:1–16.

7. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P: Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. The Journal of antimicrobial chemotherapy 2006, 57(4):720–723.

8. Rennels ML, Gregory TF, Blaumanis OR, Fujimoto K, Grady PA: Evidence for a paravascular fluid circulation in the mammalian central nervous system, provided by the rapid distribution of tracer protein throughout the brain from the subarachnoid space. Brain research 1985, 326(1):47–63.

9. Tuomanen E, Liu H, Hengstler B, Zak O, Tomasz A: Evidence for meningal inflammation by components of the pneumococcal cell wall. The Journal of infectious diseases 1985, 151(3):859–868.

10. Meli DN, Christen S, Leib SL, Tauber MG: Current insights in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Current opinion in infectious diseases 2002, 15(3):253–257.

11. Anastasiou DM, Thome GM, Luperchio SA, Alder JD: In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin. International journal of antimicrobial agents 2006, 28(5):385–388.

12. Silverman JA, Perlmutter NG, Shapiro HM: Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003, 47(8):2538–2544.

13. Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P: Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by (3)H-chlorine release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother 2007, 51(6):2249–2252.

14. Grandgirard D, Leib SL: Meningitis in Neonates: Bench to Bedside. Clinics in Perinatolog 2010, 37(3):655–676.

15. Grandgirard D, Steiner O, Tauber MG, Leib SL: An infant mouse model of brain damage in pneumococcal meningitis. Acta neurophysiologica 2007, 114(6):609–617.

16. Grandgirard D, Schurch C, Cottagnoud P, Leib SL: Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2007, 51(6):2173–2178.

17. Barchello T, Dos Santos I, Savi GD, Simoes LR, Generoso JS, Comim CM, Sachs D, Teixeira AL, Quevedo J: Depression-like behavior and proinflammatory interleukine levels in the brain of rats submitted to pneumococcal meningitis. Brain research bulletin 2010, 82(5–6):243–246.

18. Barchello T, dos Santos I, Savi GD, Florentino AF, Silvestre C, Comim CM, Feier G, Sachs D, Teixeira MM, Teixeira AL, et al: Tumor necrosis factor alpha (TNF-alpha) levels in the brain and cerebrospinal fluid after meningitis induced by Streptococcus pneumoniae. Neurosci Lett 2009, 467(1):217–219.

19. Irazusta JE, Pretzlaff RK, Zingarelli B, Xue V, Zemann F: Modulation of nuclear factor-kappaB activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis. Crit Care Med 2002, 30(11):2533–2539.

20. Irazusta J, Pretzlaff RK, Zingarelli B: Caspases inhibition decreases neuronal sequelae in meningitis. Crit Care Med 2008, 36(5):1603–1606.

21. Vianna MR, Alonso M, Viola H, Quevedo J, de Paris F, Furman M, de Stein MI, Medina JH, Izquierdo I: Role of hippocampal signaling pathways in long-term memory formation of a nonassociative learning task in the rat. Learning & memory (Cold Spring Harbor, NY) 2000, 7(5):333–340.

22. de Lima VN, Laranja DC, Bromberg E, Roessler R, Schroder N: Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats. Behavioural brain research 2005, 156(1):139–143.

23. Quevedo J, Vianna M, Ranatta MS, Roessler R, Izquierdo I, Jerusalinsky D, Quillfeldt JA: Involvement of mechanisms dependent on NMDA receptors, nitric oxide and protein kinase A in the hippocampus but not in the caudate nucleus in memory. Behav Pharmacol 1997, 8(8):713–717.

24. Roessler R, Schroder N, Vianna MR, Quevedo J, Bromberg E, Kapczinski F, Ferreira MB: Differential involvement of hippocampal and amygdalar NMDA receptors in contextual and aversive aspects of inhibitory avoidance memory in rats. Brain research 2003, 975(1):207–213.

25. Izquierdo I, Barros DM, Mello e Souza T, de Souza MM, Izquierdo LA, Medina JH: Mechanisms for memory type differences. Nature 1998, 393(6686):653–656.

26. Bevilacqua LR, Kerr DS, Medina JH, Izquierdo I, Cammarota M: Inhibition of hippocampal Jun N-terminal kinase enhances short-term memory but blocks long-term memory formation and retrieval of an inhibitory avoidance task. The European journal of neuroscience 2003, 17(4):987–992.

27. Roessler R, Vianna MR, de-Paris F, Quevedo J: Memory-enhancing treatments do not reverse the impairment of inhibitory avoidance retention induced by NMDA receptor blockade. Neurobiology of learning and memory 1999, 72(3):252–258.

28. Grandgirard D, Oberson K, Buhmann A, Gaumann R, Leib SL: Attenuation of Cerebrospinal Fluid Inflammation by the Nonbacteriolytic Antibiotic Daptomycin versus That by Ceftriaxone in Experimental Pneumococcal Meningitis. Antimicrobial Agents and Chemotherapy 2010, 54(3):1323–1326.

29. Sturz K, Schmidt H, Trostdorf F, Effert H, Mader M, Nau R: Lower lipoteichoic and teichoic acid CSF concentrations during treatment of pneumococcal meningitis with non-bacteriolytic antibiotics than with ceftriaxone. Scandinavian journal of infectious diseases 1999, 31(4):367–370.

30. Barchello T, Generoso JS, Colladel A, Moreira AP, Almeida SM: Pathophysiology of acute meningitis caused by Streptococcus pneumoniae and adjunctive therapy approaches. Arquivos de neuro-psiquiatria 2012, 70(3):366–372.

31. Barchello T, dos Santos I, Savi GD, Simoes LR, Silvestre T, Comim CM, Sachs D, Teixeira WM, Teixeira AL, Quevedo J: TNF-alpha, IL-1beta, IL-6, and cinc-1 levels in rat brain after meningitis induced by Streptococcus pneumoniae.. Journal of neuroimmunology 2010, 221(1–2):42–45.

32. Tally FP, Zeckel M, Walszewski MM, Canin C, Berman CL, Dusano GL, Olesen FB Jr: Daptomycin: a novel agent for Gram-positive infections. Expert opinion on investigational drugs 1999, 8(8):1223–1238.

33. Carpenter CF, Chambers HF: Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2004, 38(7):1094–1100.

34. Cottagnoud P, Pfister M, Acosta F, Cottagnoud M, Flatz L, Kuhn F, Muller HP, Stucki A: Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004, 48(10):3928–3933.

35. Grandgirard D, Burn M, Agymorn F, Leib SL: Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrobial agents and chemotherapy 2012, 56(8):4289–4295.

36. Nau R, Effert H: Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clinical microbiology reviews 2002, 15(1):95–110.

37. Barchello T, Silva GZ, Generoso JS, Savi GD, Michelon CM, Feier G, Comim CM, Quevedo J: Time-dependent behavioral recovery after pneumococcal meningitis in rats. Journal of neural transmission (Vienna, Austria: 1996) 2010, 117(8):819–826.

Cite this article as: Barichello et al.: Attenuation of cognitive impairment by the nonbacteriolytic antibiotic daptomycin in Wistar rats submitted to pneumococcal meningitis. BMC Neuroscience 2013 14:42.